Autopsy report · NCT03400254

Gedatolisib, Hydroxychloroquine or the Combination for Prevention of Recurrent Breast Cancer ("GLACIER")

“due to business decision regarding the study drug.”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 1, Phase 2

Sponsor

Abramson Cancer Center at Penn Medicine

Sponsor type

University, hospital or other

Conditions

Breast Cancer

Interventions

Hydroxychloroquine (HCQ); Gedatolisib

Participants

0

Sites

1

Countries

United States

Trials that died the same way

• Bevacizumab vs Dacarbazine in Metastatic Melanoma
  “Lack of financing of the study drug. Not sufficient financial support.” (75% match in meaning)
• Panobinostat/Velcade in Multiple Myeloma
  “This study was terminated because the drug company stopped making the study drug” (75% match in meaning)
• P1101 in Treating Patients With Myelofibrosis
  “Study drug became commercially available” (74% match in meaning)
• An Efficacy and Safety Study for Nesiritide in Heart Failure Patients With Reduced Kidney Function Undergoing Coronary Artery Bypass Graft Surgery Requiring Cardiopulmonary Bypass (CPB Pump or Heart Lung Machine)
  “Study was withdrawn prior to patient dosing based on a business decision.” (74% match in meaning)
• Exenatide For Reducing the Reinforcing Effects of Cocaine
  “The study was closed due to the inability to acquire the study drug.” (71% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.